Orthocell has announced the accelerated market expansion of Striate+â„¢ and Remplirâ„¢, with seven regulatory applications either in progress or planned for its medical device platform products.
Quarterly Report – Period to 30 June 2024
Orthocell has today published its Quarterly Report for the period ended 30 June 2024.
Orthocell Receives Regulatory Approval to Commence Sales of Striate+â„¢ in CanadaÂ
Orthocell has received a Medical Device Licence from Health Canada, allowing the commencement of sales of its market leading dental guided bone regeneration product, Striate+â„¢, in the key market of Canada.
The Australian Business Review | Investors are all ears as Orthocell’s nerve and tissue solutions deliver record revenue
News of Orthocell’s record-breaking quarterly and full year revenue has been published in a Special Report in The Australian Business Review.Â
Business News | Orthocell posts record revenue
Orthocell’s record revenue for FY24 has been reported in Business News.
Proactive Interview | Record-breaking revenue for FY24
Orthocell Managing Director, Paul Anderson, spoke with Jonathan Jackson at Proactive to discuss the Company’s record-breaking revenue for the June 24 quarter and for FY24.
Orthocell Continues Impressive Growth with Record Quarterly and Yearly Revenue Achieved
Orthocell has announced that it has recorded impressive sales growth across its product portfolio, with total revenue for FY24 of $6.72million – up 30.40% from the previous financial year, FY23.
Petra Capital Research Report | June 2024
Petra Capital has released research report, forecasting Orthocell’s potential to reach A$1.28 per share.
Orthocell applies for TGA market approval for SmrtGraftâ„¢
Orthocell has applied to the Therapeutic Good Administration (TGA) for Australian market approval for its SmrtGraftâ„¢ tendon repair device, in preparation for its introduction into the Australian tendon repair and regeneration market.
Remplirâ„¢ nerve repair study published in peer-reviewed clinical journal
Orthocell has announced that results from the Remplirâ„¢ nerve regeneration clinical trial have been published in a high profile clinical journal.